Phase 2 Trial Completes, Investigating New Weight Management Compound NNC0174-0833
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Background
Overweight and obesity represent significant global health crises, contributing to a myriad of chronic conditions such as type 2 diabetes and cardiovascular disease. Despite existing treatments, there remains a critical need for novel therapies with improved efficacy and safety profiles. This Phase 2 study, sponsored by Novo Nordisk, aimed to comprehensively investigate the safety and efficacy of NNC0174-0833 for weight management and identify optimal dose ranges.
Study Design
Population
Patients with overweight or obesity, and associated conditions like type 2 diabetes and cardiovascular disease, were studied in this Phase 2 trial.
Intervention
The novel weight management compound NNC0174-0833 (Cagrilintide) was investigated for its safety and efficacy across various dose ranges.
Outcome
The primary endpoints were the safety and efficacy of NNC0174-0833 for weight management.
